The webinar covers pricing and reimbursement for advanced therapies, as well as addressing the regulatory and wider market access challenges and opportunities facing companies. The webinar features Thomas Lönngren, Strategic Advisor at NDA Group, Panos Kefalas, Head of Health Economics and Market Access at Cell and Gene Therapy Catapult, and Graham Tatham, Director at Simon-Kucher & Partners. Register here to listen to the on-demand webinar.
This webinar series has been developed to provide strategic insights across the key stages of a company’s development and product lifecycle. Parts one and two of the series examined funding and commercialisation. Speakers have included: Ron Philip, Head of Global Commercial at Spark Therapeutics; Rodney Rietze, Senior Investigator, Exploratory Immuno-Oncology Group at Novartis Institute for Biomedical Research; Gbola Amusa, Partner, Director of Research, and Head of Healthcare Research at Chardan; Anna French, Associate at Qiming Venture Partners; Duncan Mackay, Head of Regulatory Affairs at ERA Consulting; Dmitry Kuzmin, Managing Partner at 4BIO Capital; Lucas de Breed, Director at INKEF Capital; and Vamil Divan, Analyst at Credit Suisse. You can listen to the previous webinars in the series here.
WEBINAR SERIES: FUNDING, COMMERCIALISATION AND MARKET ACCESS FOR ADVANCED THERAPIES
Part three: Gaining market access in a challenging European environment
- Moderator: Graham Tatham, Director at Simon-Kucher & Partners
- Speaker: Thomas Lönngren, Strategic Advisor at NDA Group
- Speaker: Panos Kefalas, Head of Health Economics and Market Access at Cell and Gene Therapy Catapult
- Time and date: 2pm (BST) on Tuesday 26 June - Now available on demand
Learn more from industry leaders at Phacilitate Leaders Europe. The event will bring the whole advanced therapies ecosystem together in London on 11-12 September 2018. Qualified investors can register for free here.
Feature images © bluebay2014 – stock.adobe.com